CL2011002023A1 - Variantes del dominio variables sencillo de inmunoglobulinas anti-seroalbumina (sa) dom7h-14; ligando multiespecifico que comprende la variante de dominio sencillo de inmunoglobulina anti-sa; proteina de fusion con la variante; composicion que comprende la variante, ligando especifico o proteina de fusion. - Google Patents

Variantes del dominio variables sencillo de inmunoglobulinas anti-seroalbumina (sa) dom7h-14; ligando multiespecifico que comprende la variante de dominio sencillo de inmunoglobulina anti-sa; proteina de fusion con la variante; composicion que comprende la variante, ligando especifico o proteina de fusion.

Info

Publication number
CL2011002023A1
CL2011002023A1 CL2011002023A CL2011002023A CL2011002023A1 CL 2011002023 A1 CL2011002023 A1 CL 2011002023A1 CL 2011002023 A CL2011002023 A CL 2011002023A CL 2011002023 A CL2011002023 A CL 2011002023A CL 2011002023 A1 CL2011002023 A1 CL 2011002023A1
Authority
CL
Chile
Prior art keywords
variant
fusion protein
ligand
dom7h
immunoglobulins
Prior art date
Application number
CL2011002023A
Other languages
English (en)
Inventor
Angelis Elena De
Carolyn Enever
Haiqun Liu
Oliver Schon
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CL2011002023A1 publication Critical patent/CL2011002023A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Variante de dominio variable de inmunoglobulinas anti-albumina de suero (sa) de dom7h-14; resto de unión a anti-albúmina de suero; variante de dom7h14; ligando multiespecífico que comprende una variante anti-sa; proteína de fusión; composición que comprende variante, resto de unión, ligando específico o proteína de fusión.
CL2011002023A 2009-02-19 2011-08-18 Variantes del dominio variables sencillo de inmunoglobulinas anti-seroalbumina (sa) dom7h-14; ligando multiespecifico que comprende la variante de dominio sencillo de inmunoglobulina anti-sa; proteina de fusion con la variante; composicion que comprende la variante, ligando especifico o proteina de fusion. CL2011002023A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15374609P 2009-02-19 2009-02-19
US16399009P 2009-03-27 2009-03-27

Publications (1)

Publication Number Publication Date
CL2011002023A1 true CL2011002023A1 (es) 2012-04-09

Family

ID=42306619

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002023A CL2011002023A1 (es) 2009-02-19 2011-08-18 Variantes del dominio variables sencillo de inmunoglobulinas anti-seroalbumina (sa) dom7h-14; ligando multiespecifico que comprende la variante de dominio sencillo de inmunoglobulina anti-sa; proteina de fusion con la variante; composicion que comprende la variante, ligando especifico o proteina de fusion.

Country Status (23)

Country Link
US (2) US9175071B2 (es)
EP (1) EP2398825B1 (es)
JP (1) JP5766616B2 (es)
KR (1) KR101820968B1 (es)
CN (2) CN102405232B (es)
AR (1) AR075506A1 (es)
AU (2) AU2010215481C1 (es)
BR (1) BRPI1008705B1 (es)
CA (1) CA2753130C (es)
CL (1) CL2011002023A1 (es)
CO (1) CO6450689A2 (es)
DO (1) DOP2011000269A (es)
EA (1) EA027866B1 (es)
ES (1) ES2654929T3 (es)
IL (1) IL214481A0 (es)
MA (1) MA33052B1 (es)
MX (1) MX2011008752A (es)
PE (1) PE20120170A1 (es)
SG (1) SG173488A1 (es)
TW (1) TW201042041A (es)
UY (1) UY32452A (es)
WO (1) WO2010094722A2 (es)
ZA (1) ZA201105658B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG194383A1 (en) * 2008-12-05 2013-11-29 Glaxo Group Ltd Methods for selecting protease resistant polypeptides
KR101819754B1 (ko) 2009-02-19 2018-01-18 글락소 그룹 리미티드 개선된 항-혈청 알부민 결합 변이체
JP2012521971A (ja) * 2009-03-27 2012-09-20 グラクソ グループ リミテッド 薬物融合体および複合体
EP2483308A1 (en) * 2009-09-30 2012-08-08 Glaxo Group Limited Drug fusions and conjugates with extended half life
MX2012013406A (es) * 2010-05-20 2012-12-10 Glaxo Group Ltd Variantes de union mejoradas anti-albumina serica.
US9012609B2 (en) 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
WO2012050923A2 (en) * 2010-09-28 2012-04-19 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action
US20130266567A1 (en) 2010-12-01 2013-10-10 Haren Arulanantham Anti-serum albumin binding single variable domains
WO2012104227A1 (en) 2011-02-02 2012-08-09 Glaxo Group Limited Novel antigen binding proteins
IL263079B2 (en) 2016-05-18 2024-05-01 Modernatx Inc Relaxin-encoding polynucleotides
CA3043261A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Manufacturing optimization of gl-2045, a multimerizing stradomer
WO2018107082A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds
NZ756674A (en) 2017-02-16 2023-06-30 Sonnet Biotherapeutics Inc Albumin binding domain fusion proteins
JP7130678B2 (ja) 2017-06-05 2022-09-05 ヌマブ セラピューティクス アクチェンゲゼルシャフト 新規抗ｈｓａ抗体
WO2018224439A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
EP3807311A4 (en) * 2018-04-24 2022-01-26 National Research Council of Canada SERUM ALBUMIN BINDING ANTIBODIES FOR ADJUSTABLE HALF-LIFE EXTENSION OF BIOLOGICALS
KR102204315B1 (ko) * 2018-11-16 2021-01-18 한국세라믹기술원 인간 혈청 알부민에 특이적으로 결합하는 어피바디 및 그의 용도
WO2024097639A1 (en) * 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19713272A1 (de) 1997-03-29 1998-10-08 Junghans Uhren Gmbh Zeitzonen-Uhr
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
ES2351509T3 (es) 2004-03-24 2011-02-07 Domantis Limited Secuencia lider universal de gas1.
EP2740743A3 (en) 2004-06-01 2015-08-19 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
JP5185624B2 (ja) 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
BRPI0518762A2 (pt) 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante ou isolado, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir a fusço de droga, composiÇço farmacÊutica, mÉtodo para tratamento de um indivÍduo tendo uma doenÇa inflamatària, uso de um conjugado de droga ou fusço de droga, e, composiÇço de droga
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2688434A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
EP2358754A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Ligands that bind il-13

Also Published As

Publication number Publication date
EA027866B1 (ru) 2017-09-29
CN105061593B (zh) 2018-08-03
AR075506A1 (es) 2011-04-06
US20110300158A1 (en) 2011-12-08
AU2010215481B2 (en) 2014-02-20
AU2010215481C1 (en) 2015-06-04
US20160075774A1 (en) 2016-03-17
JP2012517819A (ja) 2012-08-09
MX2011008752A (es) 2011-09-06
AU2010215481A1 (en) 2011-08-25
EA201171067A1 (ru) 2012-02-28
SG173488A1 (en) 2011-09-29
WO2010094722A3 (en) 2011-01-13
AU2014202764A1 (en) 2014-06-12
BRPI1008705A2 (pt) 2016-03-08
KR101820968B1 (ko) 2018-01-23
JP5766616B2 (ja) 2015-08-19
ES2654929T3 (es) 2018-02-15
CA2753130C (en) 2020-07-14
US9751935B2 (en) 2017-09-05
BRPI1008705B1 (pt) 2021-05-25
EP2398825A2 (en) 2011-12-28
UY32452A (es) 2010-09-30
US9175071B2 (en) 2015-11-03
CN102405232B (zh) 2015-08-19
ZA201105658B (en) 2012-05-25
AU2014202764B2 (en) 2016-07-07
EP2398825B1 (en) 2017-10-25
IL214481A0 (en) 2011-09-27
PE20120170A1 (es) 2012-03-21
CN105061593A (zh) 2015-11-18
CA2753130A1 (en) 2010-08-26
MA33052B1 (fr) 2012-02-01
WO2010094722A2 (en) 2010-08-26
CN102405232A (zh) 2012-04-04
CO6450689A2 (es) 2012-05-31
DOP2011000269A (es) 2011-12-31
KR20110127224A (ko) 2011-11-24
TW201042041A (en) 2010-12-01

Similar Documents

Publication Publication Date Title
CL2011002023A1 (es) Variantes del dominio variables sencillo de inmunoglobulinas anti-seroalbumina (sa) dom7h-14; ligando multiespecifico que comprende la variante de dominio sencillo de inmunoglobulina anti-sa; proteina de fusion con la variante; composicion que comprende la variante, ligando especifico o proteina de fusion.
CL2011002025A1 (es) Variante de dominio variable de inmunoglobulinas anti-albumina de suero (sa) de dom7h-14; resto de union a anti-albumina de suero; variante de dom7h14; ligando multiespecifico que comprende una variante anti-sa; proteina de fusion; composicion que comprende variante, resto de union, ligando especifico o proteina de fusion.
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
EA201100869A1 (ru) Противоопухолевые комбинации, содержащие специфически распознающие cd38 антитела и циклофосфамид
CL2008000423A1 (es) Ligando que comprende un dominio variable simple de anticuerpo que se une especificamente a la albumina serica; proteina de fusion que comprende el dominio variable antes dicho.
ME01136B (me) Antitumorske kombinacije koje sadrže antitijela koja specifično prepoznaju cd38 i melfalan
PA8849901A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y la citarabina
EA201100867A1 (ru) Противоопухолевые комбинации, содержащие антитела, специфично распознающие cd38, и винкристин
CU23809A3 (es) Anticuerpo específico prlr
CR20150147A (es) Polipéptidos que contienen fc con glicosilación alterada y función efectora reducida
WO2014160160A3 (en) Antibody drug conjugates and corresponding antibodies
NO20092052L (no) Antistoffer og immunkonjugater, og anvendelser derav
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
BRPI0910844A2 (pt) conjunto de lâmpada.
HN2006015949A (es) Anticuerpos de p-caderina
ES2664972T3 (es) Moléculas de unión anti-Psl de Pseudomonas y usos de las mismas
BRPI0818865A2 (pt) Anticorpos monoclonais contra proteína c ativada.
ECSP11011190A (es) Anticuerpos monoclonales anti-rhd
CY1118233T1 (el) Καινουργια αντιβιοτικα bacitracin
BRPI0715544A2 (pt) Anticorpos que modificam doença cancerosas.
CR8839S (es) Paquete particularmente util para articulos de fumador
BRPI0718609A2 (pt) Anticorpos modificadores de doença cancerosa.
TR200805557U (tr) Sulama tankerleri için otomatik yönlendirme mekanizması
PA8596301A1 (es) Polimorfos de inhibidores de proteina quinasa de 2-indolinona sustituida con pirrol